

HERAMED LIMITED COMPLETES \$3.1 MILLION PLACEMENT

- Firm commitments of \$3.1 million (before costs) in a two-tranche Placement to sophisticated and professional investors
- \$3.1million Placement at 1.7 cents per share, a ~19% discount to the 15-day VWAP of 2.1 cents
- The proceeds of the Placement will be used to support commercial deployments, pilots and integration of HeraCARE into large health systems, private clinics and a number of platforms in the US, Australia, and Europe.

HeraMED Limited (ASX: HMD) ('HeraMED' or the 'Company'), a medical data and technology company leading the digital transformation of maternity care, is pleased to announce it has received firm commitments for a two-tranche private Placement (the "**Placement**") of \$3.1 million (before costs) to sophisticated and professional investors.

HeraMED Managing Director and CEO, Anoushka Gungadin, commented, "We are delighted to secure \$3.1 million in firm commitments, which demonstrates strong investor confidence in HeraMED's vision and potential. The problem of access to care, midwife shortages and cost of care continues to deepen around the globe and we continue to build our evidence base that HeraCARE can be a solution for each of these problems. This capital raise comes at a pivotal time as we gain significant traction with our HeraCARE platform, exemplified by our recent successful implementation at Broward Health, one of the largest public healthcare systems in the U.S.

The funds raised will be instrumental in executing our Four-Point Strategic Plan, supporting commercial deployments and the integration of HeraCARE into large health systems, private clinics, and various platforms across the US, Australia, and Europe as well as evidence-based research, grant applications, further strategic partnerships and lifting women's health.

We are excited about the opportunities this funding unlocks, allowing us to accelerate our growth strategy and expand our reach in key markets. On behalf of HeraMED, I extend our sincere gratitude to our investors for their support and belief in our mission to revolutionise maternity care through innovative digital health solutions."

About the Placement

HeraMED has received firm commitments to raise \$3.1 million (before costs) via the issue of 182,352,924 new ordinary shares, at 1.7 cents per share in a two-tranche private Placement. The issue price is a 19% discount to the 15-day VWAP of 2.1 cents before HeraMED went into trading halt pre-market on Monday, 21st October 2024.

Tranche 1 of the Placement will be issued under the Company's capacity under ASX Listing Rule 7.1 (90,987,472 ordinary shares) and 7.1A (63,324,981 ordinary shares) raising approx. \$2.623 million at 1.7 cents per share. Tranche 2 of the Placement is subject to shareholder approval at an upcoming EGM to approve the Company raising \$476,688 via the issue of 28,040,471 ordinary shares on the same terms as Tranche 1.

The proceeds of the Placement will fund working capital to support commercial deployments, pilots and integration of HeraCARE into large health systems, private clinics and a number of platforms across Australia, US and Europe.

Westar Capital Limited was engaged as Lead Manager to the Placement and receives a 6% capital raising fee and will also receive 50 million options with an exercise price of 2 cents with an expiry date four years from the date of issue subject to shareholder approval.

The indicative timetable for the Placement is as follows:

| Summary of key dates | Date/Time |
|----------------------------------------------------------|------------------|
| ASX Announcement of Offer | 23 October 2024 |
| Trade Date | 23 October 2024 |
| Settlement of Tranche 1 Placement Shares | 28 October 2024 |
| Allotment and trading of Tranche 1 Placement Shares | 29 October 2024 |
| EGM - to approve the issue of Tranche 2 Placement Shares | 12 December 2024 |
| Settlement of Tranche 2 Placement Shares | 16 December 2024 |
| Allotment and trading of Tranche 2 Placement Shares | 17 December 2024 |

The above timetable is indicative only and may change without notice.

ENDS

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited
Managing Director & CEO
Anoushka Gungadin
M: +61 431 131 649
E: anoushka@hera-med.com

CFO & Company Secretary
Cameron Jones
T: +61 400 086 399
E: cameron.jones@bio101.com

Chairman
Tim Chapman
T: +61 419 897 062
E: tchapman@claritycap.com.au

About HeraMED Limited (ASX: HMD)

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.